Cargando...
HER2 status and disparities in luminal breast cancers
National Comprehensive Care Network guidelines for adjuvant treatment of invasive breast cancer are based on HER2 and hormone receptor (HR) status, where HR+ disease encompasses all estrogen receptor (ER)+ and/or progesterone receptor (PR)+ tumors. We sought to explore clinical and demographic diffe...
Gardado en:
Publicado en: | Cancer Med |
---|---|
Main Authors: | , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado: |
John Wiley and Sons Inc.
2016
|
Assuntos: | |
Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4893351/ https://ncbi.nlm.nih.gov/pubmed/27250116 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.757 |
Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|